Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism

NACompletedINTERVENTIONAL
Enrollment

431

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2021

Study Completion Date

August 31, 2024

Conditions
Graves' Hyperthyroidism
Interventions
DIETARY_SUPPLEMENT

Selenium

100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.

OTHER

Placebo

Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.

Trial Locations (8)

Unknown

Department of Endocrinology and Gastroenterology, Bispebjerg Hospital, Copenhagen

Department of Medical Endocrinology, Rigshospitalet, Copenhagen

Department of Endocrinology, Hospital of Southwest Denmark, Esbjerg

Department of Medicine, Gentofte Hospital, Gentofte Municipality

Department of Internal Medicine O 106, Endocrine Unit, Herlev Hospital, Herlev

Department of Cardiology and Endocrinology, Endocrine Unit, Hillerød Hospital, Hillerød

Department of Endocrinology, Section 541, Hvidovre Hospital, Hvidovre

Department of Endocrinology and Metabolism, Odense University Hospital, Odense

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

collaborator

Esbjerg Hospital - University Hospital of Southern Denmark

OTHER

collaborator

Herlev Hospital

OTHER

collaborator

Bispebjerg Hospital

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

Hillerod Hospital, Denmark

OTHER

collaborator

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

collaborator

Danish Council for Independent Research

OTHER

collaborator

The Danish Council for Strategic Research

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT01611896 - Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism | Biotech Hunter | Biotech Hunter